^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    FGF8 (Fibroblast Growth Factor 8)

    i
    Other names: FGF8, Fibroblast Growth Factor 8, AIGF, Androgen-Induced Growth Factor, Fibroblast Growth Factor 8 (Androgen-Induced), Heparin-Binding Growth Factor 8, HBGF-8, FGF-8, KAL6, HH6
    Associations

    News

    Trials
    2ms
    Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma. (PubMed, Mol Cancer Ther)
    These findings indicate that FGF8 exerts oncogenic effects in FP-RMS via FGFR4 and may exert oncogenic effects in P3F-independent relapses via FGFR1. Our study reveals the functional significance of FGF8 in FP-RMS and provides a rationale for preclinical studies of FGFR inhibitors in FP-RMS.
    Journal
    |
    FGFR4 (Fibroblast growth factor receptor 4) • FGF8 (Fibroblast Growth Factor 8) • PAX3 (Paired Box 3)
    3ms
    Involvement of the FGF8/FGF receptor signaling pathway in the maintenance and progression of fusion-positive rhabdomyosarcoma. (PubMed, Mol Cancer Ther)
    These findings indicate that FGF8 exerts oncogenic effects in FP-RMS via FGFR4 and may exert oncogenic effects in P3F-independent relapses via FGFR1. Our study reveals the functional significance of FGF8 in FP-RMS and provides a rationale for preclinical studies of FGFR inhibitors in FP-RMS.
    Journal
    |
    FGFR4 (Fibroblast growth factor receptor 4) • FGF8 (Fibroblast Growth Factor 8) • PAX3 (Paired Box 3)
    4ms
    Fibroblast Growth Factor 8 Suppresses Neurotoxic Astrocytes and Alleviates Neuropathic Pain via Spinal FGFR3 Signaling. (PubMed, Neurosci Bull)
    Fibroblast growth factor 8 (FGF8), a neuroprotective factor via FGFR3, mitigated microglia-induced C3⁺ astrocyte reactivity in vitro and suppressed spinal C3 expression and mechanical allodynia following intrathecal administration in SNI mice. These findings reveal a microglia-astrocyte signaling axis that promotes A1 reactivity and position FGF8 as a promising therapeutic candidate for neuropathic pain by modulating astrocyte heterogeneity.
    Journal
    |
    FGFR3 (Fibroblast growth factor receptor 3) • TNFA (Tumor Necrosis Factor-Alpha) • FGF8 (Fibroblast Growth Factor 8)
    8ms
    Nanocarrier mediated DOX/siRNA targeted co-delivery for synergistic treatment of cutaneous melanoma in outdoor athletes. (PubMed, Sci Rep)
    Herein, the folate-biotin-quaternized starch nanoparticles (FBqS NPs) were used as a co-loading platform to deliver doxorubicin (DOX) and siRNAIGF1R into human malignant melanoma cell lines (A375 cells) in vitro...The endocytosis mediated by clathrin, caveolae and folate-receptor were the main pathways for A375 cells to swallow drug-loaded FBqS NPs. Therefore, the FBqS NPs were expected to achieve superior results in the combination treatment of chemotherapeutics and gene drugs for CM, which might be beneficial to athletes with CM.
    Journal
    |
    FGF8 (Fibroblast Growth Factor 8)
    |
    doxorubicin hydrochloride
    10ms
    A Cyanobacteria-derived RNA aptamer resensitizes prostate cancer to hormone therapy. (PubMed, Cancer Res)
    Accordingly, the L-Gln-depleting aptamer, with demonstrated serum stability, limited the proliferation and promoted cell death of castration-resistant PCa alone and in combination therapy with AR antagonists, enzalutamide and apalutamide, in subcutaneous and orthotopic mouse models. The functionalized nanoparticle demonstrated superior anti-tumor efficacy in an orthotopic PCa model over the untargeted aptamer. The anti-tumor activity of the aptamer helped support L-Gln as an oncometabolite in PCa that can be targeted to sensitize tumors to hormone therapy.
    Journal
    |
    FOXM1 (Forkhead Box M1) • FGF8 (Fibroblast Growth Factor 8)
    |
    Xtandi (enzalutamide) • apalutamide
    12ms
    Identifcation of the FGF family as therapeutic targets and prognostic biomarkers in the microenvironment of head and neck squamous cell carcinoma. (PubMed, SLAS Technol)
    Our data may shed new light on the choice of immunotherapeutic targets and predictive biomarkers in HNSC.
    Journal • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • FGF19 (Fibroblast growth factor 19) • CD4 (CD4 Molecule) • LYN (LYN Proto-Oncogene Src Family Tyrosine Kinase) • SYK (Spleen tyrosine kinase) • AURKB (Aurora Kinase B) • FGF (Fibroblast Growth Factor) • FGF21 (Fibroblast Growth Factor 21) • ATF4 (Activating Transcription Factor 4) • FGF23 (Fibroblast Growth Factor 23) • MAP3K8 (Mitogen-Activated Protein Kinase Kinase Kinase 8) • BUB1 (BUB1 Mitotic Checkpoint Serine/Threonine Kinase) • CAMK2A (Calcium/Calmodulin Dependent Protein Kinase II Alpha) • FGF7 (Fibroblast Growth Factor 7) • FGF8 (Fibroblast Growth Factor 8) • MAP2K3 (Mitogen-Activated Protein Kinase Kinase 3) • MAPK3 (Mitogen-Activated Protein Kinase 3) • RELA (RELA Proto-Oncogene)
    12ms
    A Cross-Sectional Exploratory Study of Rat Sarcoid (Ras) Activation in Women with and Without Polycystic Ovary Syndrome. (PubMed, Cells)
    After stratifying for BMI ≤ 29.9 kg/m2, EGFR FGF8, FGFR1 VEGF-D, IGF1, and IGF-1sR differed (p < 0.05) though EGF1, EGFRvIII, FGF8, FGFR1, and VEGF-D no longer differed; after subsequently stratifying for HOMA-IR, only FGFR1, VEGF-D, IGF1, and IGF-1sR differed between groups (p < 0.05). Several growth factors that activate Ras differ between women with and without PCOS, and when stratified for BMI and HOMA-IR, only FGFR1, VEGF-D, IGF1, and IGF-1sR differed; these appear to be inherent features of the pathophysiology of PCOS.
    Preclinical • Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • FGFR1 (Fibroblast growth factor receptor 1) • HRAS (Harvey rat sarcoma viral oncogene homolog) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • IGF1 (Insulin-like growth factor 1) • VEGFD (Vascular Endothelial Growth Factor D) • FGF8 (Fibroblast Growth Factor 8) • RASA1 (RAS P21 Protein Activator 1)
    over1year
    Overexpression of Fibroblast Growth Factor 8 Is a Predictor of Impaired Survival in Esophageal Squamous Cell Carcinoma and Correlates with ALK/EML4 Alteration. (PubMed, Cancers (Basel))
    FGF8 overexpression is an adverse independent prognostic factor in patients with upfront resected ESCC. Furthermore, FGF8 expression significantly correlates with ALK and EML4 amplification and may therefore qualify as a future therapeutic target.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4) • FGF (Fibroblast Growth Factor) • FGF8 (Fibroblast Growth Factor 8)
    |
    ALK fusion
    over1year
    Dependence of PAX3-FOXO1 chromatin occupancy on ETS1 at important disease-promoting genes exposes new targetable vulnerability in Fusion-Positive Rhabdomyosarcoma. (PubMed, Oncogene)
    We additionally show that, in some FP-RMS, KDM3A also increases PAX3-FOXO1 levels. Together, our studies illuminate mechanisms of action of the KDM3A/ETS1 regulatory module, and reveal novel targetable mechanisms of PAX3-FOXO1 chromatin complex regulation, in FP-RMS.
    Journal
    |
    FOXO1 (Forkhead box O1) • ETS1 (ETS Proto-Oncogene 1) • PODXL (Podocalyxin) • FGF8 (Fibroblast Growth Factor 8) • IL4R (Interleukin 4 Receptor) • KDM3A (Lysine Demethylase 3A) • PAX3 (Paired Box 3)
    |
    PAX3-FOXO1 fusion
    over1year
    Fgf17: A regulator of the mid/hind brain boundary in mammals. (PubMed, Differentiation)
    Altered FGF17 expression has been observed in several cancers, including prostate cancer, hematopoietic cancers (acute myeloid leukemia and acute lymphoblastic leukemia), glioblastomas, perineural invasion in cervical cancer, and renal cell carcinomas. Furthermore, FGF17 has demonstrated neuroprotective effects, particularly during ischemic stroke, and has been shown to improve cognitive function in ageing mice.
    Journal
    |
    FGFR1 (Fibroblast growth factor receptor 1) • FGF8 (Fibroblast Growth Factor 8)
    over1year
    Proteomics and Bioinformatics Investigations Link Overexpression of FGF8 and Associated Hub Genes to the Progression of Ovarian Cancer and Poor Prognosis. (PubMed, Biochem Res Int)
    Subsequently, the expression of hub genes was correlated with patient survival and regulation of the tumor microenvironment. Conclusively, FGF8 and associated hub genes help in the progression of ovarian cancer, and their overexpression may lead to higher immune infiltration, poor prognosis, and poor survival.
    Journal
    |
    FGF8 (Fibroblast Growth Factor 8)
    over1year
    Diverse Responses of Oligodendrocytes to Different FGF-Family Members: Uncoupling Structure-Function Relationship Within FGF Subfamilies. (PubMed, ASN Neuro)
    Furthermore, we noted that structurally similar FGFs within subfamilies did not always show similarities in their biological effects on OL-lineage cells. Taken together, these studies reveal that FGFs differ in the way they regulate the OL-lineage cells, emphasizes the selectivity and importance of HSPGs as FGF co-receptors in OL-lineage cells and suggests that structural similarity among FGF-subfamily members may not always predict their overlapping biological functions.
    Journal
    |
    FGF4 (Fibroblast growth factor 4) • FGF2 (Fibroblast Growth Factor 2) • FGF (Fibroblast Growth Factor) • FGF8 (Fibroblast Growth Factor 8)